Pacira BioSciencesPCRX +3.34%75 Interest Coverage is 1.46 as of Mar. 2026, which is 20% below its 10-year median of 1.83. GuruFocus rates PCRX with a GF Score™ of 75/100 and a GF Value™ of $29.64 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 685 Drug Manufacturers companies, Pacira BioSciences ranks worse than 91.82% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pacira BioSciences's
Operating Income
for the
three
months ended in Mar. 2026 was $4.6 Mil. Pacira BioSciences's Interest Expense for the
three
months ended in Mar. 2026 was $-3.2 Mil.
Pacira BioSciences's interest coverage for the quarter that ended in Mar. 2026 was 1.46.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pacira BioSciences's Interest Coverage or its related term are showing as below:
PCRX'
s Interest Coverage Range Over the Past 10 Years
Min: 0.48 Med: 1.83 Max: 6.69
Current: 1.14
PCRX's Interest Coverage is ranked worse than 91.82% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs PCRX: 1.14
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pacira BioSciences Interest Coverage Related Terms
Pacira BioSciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PCRX vs ETON, AMPH, BIOA: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Interest Coverage of 1.46 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pacira BioSciences and its competitors. This is 20% below median its historical median of 1.83. Over the past decade, Pacira BioSciences' Interest Coverage has ranged from 0.48 to 6.69. According to the industry distribution chart, Pacira BioSciences ranks #629 out of 685 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Pacira BioSciences' Interest Coverage too high?
Pacira BioSciences' current Interest Coverage of 1.46 is 20% below median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 6.69. The Drug Manufacturers industry median Interest Coverage is 12.75. Pacira BioSciences' value of 1.46 is 88.5% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #629 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Interest Coverage compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #629 out of 685 companies for Interest Coverage. This places Pacira BioSciences in the lower half of its industry. The industry median Interest Coverage is 12.75. Pacira BioSciences' value of 1.46 is 88.5% below this benchmark. Historically, Pacira BioSciences' own Interest Coverage has ranged from 0.48 to 6.69 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 12.75, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Interest Coverage of 1.46 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Interest Coverage is 1.46, which is 20% below median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.64, compared to a current price of $26.45 — trading 10.8% below its estimated fair value. The current Interest Coverage is 1.46, which is 20% below median its 10-year median of 1.83 and 88.5% below the Drug Manufacturers industry median of 12.75. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Interest Coverage is 1.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $26.45 is trading 10.8% below its estimated GF Value™ of $29.64.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Interest Coverage: 1.46 (20% below median its 10-year median of 1.83)
GF Value™: $29.64 vs. price of $26.45 (10.8% below fair value)
Industry Position: 88.5% below the Drug Manufacturers median (#629 of 685)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for PCRX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
